Western blot studies showed that the administration of CM treatment to the NAFLD+CM group of animals boosted the hepatic and extrahepatic expression of PPAR-α, PPAR-γ, and CPT1A and normalized the FABP1 proteins. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.